The impact of GPIbα on platelet‐targeted FVIII gene therapy in hemophilia A mice with pre‐existing anti‐FVIII immunity

Essentials Platelet‐specific FVIII gene therapy is effective in hemophilia A mice even with inhibitors. The impact of platelet adherence via VWF/GPIbα binding on platelet gene therapy was investigated. GPIbα does not significantly affect platelet gene therapy of hemophilia A with inhibitors. Platele...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of thrombosis and haemostasis 2019-03, Vol.17 (3), p.449-459
Hauptverfasser: Chen, Juan, Schroeder, Jocelyn A., Luo, Xiaofeng, Montgomery, Robert R., Shi, Qizhen
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 459
container_issue 3
container_start_page 449
container_title Journal of thrombosis and haemostasis
container_volume 17
creator Chen, Juan
Schroeder, Jocelyn A.
Luo, Xiaofeng
Montgomery, Robert R.
Shi, Qizhen
description Essentials Platelet‐specific FVIII gene therapy is effective in hemophilia A mice even with inhibitors. The impact of platelet adherence via VWF/GPIbα binding on platelet gene therapy was investigated. GPIbα does not significantly affect platelet gene therapy of hemophilia A with inhibitors. Platelet gene therapy induces immune tolerance in hemophilia A mice with pre‐existing immunity. Summary Background We have previously demonstrated that von Willebrand factor (VWF) is essential in platelet‐specific FVIII (2bF8) gene therapy of hemophilia A (HA) with inhibitory antibodies (inhibitors). At the site of injury, platelet adherence is initiated by VWF binding to the platelet GPIb complex. Objective To investigate the impact of GPIbα on platelet gene therapy of HA with inhibitors. Methods Platelet‐FVIII expression was introduced by 2bF8 lentivirus (2bF8LV) transduction of hematopoietic stem cells (HSCs) from GPIbαnull (Ibnull) mice or rhF8‐primed FVIIInull (F8null) mice followed by transplantation into lethally irradiated rhF8‐primed F8null recipients. Animals were analyzed by flow cytometry, FVIII assays and the tail bleeding test. Results After transplantation, 99% of platelets were derived from donors. The macrothrombocytopenia phenotype was maintained in F8null mice that received 2bF8LV‐transduced Ibnull HSCs (2bF8‐Ibnull/F8null). The platelet‐FVIII expression level in 2bF8‐Ibnull/F8null recipients was similar to that obtained from F8null mice that received 2bF8LV‐transduced F8null HSCs (2bF8‐F8null/F8null). The tail bleeding test showed that the remaining hemoglobin level in the 2bF8‐Ibnull/F8null group was significantly higher than in the F8null control group, but there was no significant difference between the 2bF8‐Ibnull/F8null and 2bF8‐F8null/F8null groups. The half‐life of inhibitor disappearance time was comparable between the 2bF8‐Ibnull/F8null and 2bF8‐F8null/F8null groups. The rhF8 re‐challenge did not elicit a memory immune response once inhibitor titers dropped to undetectable levels after 2bF8 gene therapy. Conclusion GPIbα does not significantly impact platelet gene therapy of HA with inhibitors. 2bF8 gene therapy restores hemostasis and promotes immune tolerance in HA mice with pre‐existing immunity.
doi_str_mv 10.1111/jth.14379
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6397061</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2164102135</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3589-fb566e990bc4fe96ca0cee563e18bc1b88d4e2f39feeac15c44bc0e6c3ec02f83</originalsourceid><addsrcrecordid>eNp1kU9u1DAUhy1ERf_AggsgS2zoYlo7Tpx4g1RVtA2q1C4GtpbjeZl4lNjBdlpmgcQRuAoX4RCcBNO0FSDhzfPT-_zpWT-EXlJyRNM53sTuiOasFE_QHi1YtSgrxp8-3AVju2g_hA0hVBQZeYZ2GeFEZGWxh74sO8BmGJWO2LX4_LpufnzHzuKxVxF6iD-_fovKryHCCp99rOsar8ECjh14NW6xsbiDwY2d6Y3CJ3gwGvCtiR0ePaS38NmEaOwaKxtN6meFGYbJmrh9jnZa1Qd4cV8P0Iezd8vTi8Xl1Xl9enK50KyoxKJtCs5BCNLovAXBtSIaoOAMaNVo2lTVKoesZaIFUJoWOs8bTYBrBppkbcUO0NvZO07NACsNNnrVy9GbQfmtdMrIvyfWdHLtbiRnoiScJsGbe4F3nyYIUQ4maOh7ZcFNQWaU55RklBUJff0PunGTt-l7iaq4KDPGs0QdzpT2LgQP7eMylMjfocoUqrwLNbGv_tz-kXxIMQHHM3Bretj-3yTfLy9m5S8mebFa</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2186972362</pqid></control><display><type>article</type><title>The impact of GPIbα on platelet‐targeted FVIII gene therapy in hemophilia A mice with pre‐existing anti‐FVIII immunity</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Chen, Juan ; Schroeder, Jocelyn A. ; Luo, Xiaofeng ; Montgomery, Robert R. ; Shi, Qizhen</creator><creatorcontrib>Chen, Juan ; Schroeder, Jocelyn A. ; Luo, Xiaofeng ; Montgomery, Robert R. ; Shi, Qizhen</creatorcontrib><description>Essentials Platelet‐specific FVIII gene therapy is effective in hemophilia A mice even with inhibitors. The impact of platelet adherence via VWF/GPIbα binding on platelet gene therapy was investigated. GPIbα does not significantly affect platelet gene therapy of hemophilia A with inhibitors. Platelet gene therapy induces immune tolerance in hemophilia A mice with pre‐existing immunity. Summary Background We have previously demonstrated that von Willebrand factor (VWF) is essential in platelet‐specific FVIII (2bF8) gene therapy of hemophilia A (HA) with inhibitory antibodies (inhibitors). At the site of injury, platelet adherence is initiated by VWF binding to the platelet GPIb complex. Objective To investigate the impact of GPIbα on platelet gene therapy of HA with inhibitors. Methods Platelet‐FVIII expression was introduced by 2bF8 lentivirus (2bF8LV) transduction of hematopoietic stem cells (HSCs) from GPIbαnull (Ibnull) mice or rhF8‐primed FVIIInull (F8null) mice followed by transplantation into lethally irradiated rhF8‐primed F8null recipients. Animals were analyzed by flow cytometry, FVIII assays and the tail bleeding test. Results After transplantation, 99% of platelets were derived from donors. The macrothrombocytopenia phenotype was maintained in F8null mice that received 2bF8LV‐transduced Ibnull HSCs (2bF8‐Ibnull/F8null). The platelet‐FVIII expression level in 2bF8‐Ibnull/F8null recipients was similar to that obtained from F8null mice that received 2bF8LV‐transduced F8null HSCs (2bF8‐F8null/F8null). The tail bleeding test showed that the remaining hemoglobin level in the 2bF8‐Ibnull/F8null group was significantly higher than in the F8null control group, but there was no significant difference between the 2bF8‐Ibnull/F8null and 2bF8‐F8null/F8null groups. The half‐life of inhibitor disappearance time was comparable between the 2bF8‐Ibnull/F8null and 2bF8‐F8null/F8null groups. The rhF8 re‐challenge did not elicit a memory immune response once inhibitor titers dropped to undetectable levels after 2bF8 gene therapy. Conclusion GPIbα does not significantly impact platelet gene therapy of HA with inhibitors. 2bF8 gene therapy restores hemostasis and promotes immune tolerance in HA mice with pre‐existing immunity.</description><identifier>ISSN: 1538-7933</identifier><identifier>ISSN: 1538-7836</identifier><identifier>EISSN: 1538-7836</identifier><identifier>DOI: 10.1111/jth.14379</identifier><identifier>PMID: 30609275</identifier><language>eng</language><publisher>England: Elsevier Limited</publisher><subject>Animals ; Antibodies - immunology ; Bleeding ; Blood Platelets - immunology ; Blood Platelets - metabolism ; Disease Models, Animal ; Factor VIII - genetics ; Factor VIII - immunology ; Factor VIII - metabolism ; Factor VIII deficiency ; Flow cytometry ; FVIII ; Gene therapy ; Genetic Therapy ; GPIbα ; Hematopoietic Stem Cell Transplantation ; Hematopoietic stem cells ; Hematopoietic Stem Cells - metabolism ; Hemoglobin ; Hemophilia ; hemophilia A ; Hemophilia A - blood ; Hemophilia A - genetics ; Hemophilia A - immunology ; Hemophilia A - therapy ; Hemostasis ; Immune response ; Immune Tolerance ; Immunological memory ; Immunological tolerance ; Mice, Knockout ; Phenotypes ; platelet ; Platelet Adhesiveness ; Platelet Glycoprotein GPIb-IX Complex - genetics ; Platelet Glycoprotein GPIb-IX Complex - metabolism ; Platelets ; Stem cell transplantation ; Stem cells ; Transduction, Genetic ; Von Willebrand factor ; von Willebrand Factor - metabolism</subject><ispartof>Journal of thrombosis and haemostasis, 2019-03, Vol.17 (3), p.449-459</ispartof><rights>2019 International Society on Thrombosis and Haemostasis</rights><rights>2019 International Society on Thrombosis and Haemostasis.</rights><rights>Copyright © 2019 International Society on Thrombosis and Haemostasis</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3589-fb566e990bc4fe96ca0cee563e18bc1b88d4e2f39feeac15c44bc0e6c3ec02f83</citedby><cites>FETCH-LOGICAL-c3589-fb566e990bc4fe96ca0cee563e18bc1b88d4e2f39feeac15c44bc0e6c3ec02f83</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27923,27924</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30609275$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Chen, Juan</creatorcontrib><creatorcontrib>Schroeder, Jocelyn A.</creatorcontrib><creatorcontrib>Luo, Xiaofeng</creatorcontrib><creatorcontrib>Montgomery, Robert R.</creatorcontrib><creatorcontrib>Shi, Qizhen</creatorcontrib><title>The impact of GPIbα on platelet‐targeted FVIII gene therapy in hemophilia A mice with pre‐existing anti‐FVIII immunity</title><title>Journal of thrombosis and haemostasis</title><addtitle>J Thromb Haemost</addtitle><description>Essentials Platelet‐specific FVIII gene therapy is effective in hemophilia A mice even with inhibitors. The impact of platelet adherence via VWF/GPIbα binding on platelet gene therapy was investigated. GPIbα does not significantly affect platelet gene therapy of hemophilia A with inhibitors. Platelet gene therapy induces immune tolerance in hemophilia A mice with pre‐existing immunity. Summary Background We have previously demonstrated that von Willebrand factor (VWF) is essential in platelet‐specific FVIII (2bF8) gene therapy of hemophilia A (HA) with inhibitory antibodies (inhibitors). At the site of injury, platelet adherence is initiated by VWF binding to the platelet GPIb complex. Objective To investigate the impact of GPIbα on platelet gene therapy of HA with inhibitors. Methods Platelet‐FVIII expression was introduced by 2bF8 lentivirus (2bF8LV) transduction of hematopoietic stem cells (HSCs) from GPIbαnull (Ibnull) mice or rhF8‐primed FVIIInull (F8null) mice followed by transplantation into lethally irradiated rhF8‐primed F8null recipients. Animals were analyzed by flow cytometry, FVIII assays and the tail bleeding test. Results After transplantation, 99% of platelets were derived from donors. The macrothrombocytopenia phenotype was maintained in F8null mice that received 2bF8LV‐transduced Ibnull HSCs (2bF8‐Ibnull/F8null). The platelet‐FVIII expression level in 2bF8‐Ibnull/F8null recipients was similar to that obtained from F8null mice that received 2bF8LV‐transduced F8null HSCs (2bF8‐F8null/F8null). The tail bleeding test showed that the remaining hemoglobin level in the 2bF8‐Ibnull/F8null group was significantly higher than in the F8null control group, but there was no significant difference between the 2bF8‐Ibnull/F8null and 2bF8‐F8null/F8null groups. The half‐life of inhibitor disappearance time was comparable between the 2bF8‐Ibnull/F8null and 2bF8‐F8null/F8null groups. The rhF8 re‐challenge did not elicit a memory immune response once inhibitor titers dropped to undetectable levels after 2bF8 gene therapy. Conclusion GPIbα does not significantly impact platelet gene therapy of HA with inhibitors. 2bF8 gene therapy restores hemostasis and promotes immune tolerance in HA mice with pre‐existing immunity.</description><subject>Animals</subject><subject>Antibodies - immunology</subject><subject>Bleeding</subject><subject>Blood Platelets - immunology</subject><subject>Blood Platelets - metabolism</subject><subject>Disease Models, Animal</subject><subject>Factor VIII - genetics</subject><subject>Factor VIII - immunology</subject><subject>Factor VIII - metabolism</subject><subject>Factor VIII deficiency</subject><subject>Flow cytometry</subject><subject>FVIII</subject><subject>Gene therapy</subject><subject>Genetic Therapy</subject><subject>GPIbα</subject><subject>Hematopoietic Stem Cell Transplantation</subject><subject>Hematopoietic stem cells</subject><subject>Hematopoietic Stem Cells - metabolism</subject><subject>Hemoglobin</subject><subject>Hemophilia</subject><subject>hemophilia A</subject><subject>Hemophilia A - blood</subject><subject>Hemophilia A - genetics</subject><subject>Hemophilia A - immunology</subject><subject>Hemophilia A - therapy</subject><subject>Hemostasis</subject><subject>Immune response</subject><subject>Immune Tolerance</subject><subject>Immunological memory</subject><subject>Immunological tolerance</subject><subject>Mice, Knockout</subject><subject>Phenotypes</subject><subject>platelet</subject><subject>Platelet Adhesiveness</subject><subject>Platelet Glycoprotein GPIb-IX Complex - genetics</subject><subject>Platelet Glycoprotein GPIb-IX Complex - metabolism</subject><subject>Platelets</subject><subject>Stem cell transplantation</subject><subject>Stem cells</subject><subject>Transduction, Genetic</subject><subject>Von Willebrand factor</subject><subject>von Willebrand Factor - metabolism</subject><issn>1538-7933</issn><issn>1538-7836</issn><issn>1538-7836</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kU9u1DAUhy1ERf_AggsgS2zoYlo7Tpx4g1RVtA2q1C4GtpbjeZl4lNjBdlpmgcQRuAoX4RCcBNO0FSDhzfPT-_zpWT-EXlJyRNM53sTuiOasFE_QHi1YtSgrxp8-3AVju2g_hA0hVBQZeYZ2GeFEZGWxh74sO8BmGJWO2LX4_LpufnzHzuKxVxF6iD-_fovKryHCCp99rOsar8ECjh14NW6xsbiDwY2d6Y3CJ3gwGvCtiR0ePaS38NmEaOwaKxtN6meFGYbJmrh9jnZa1Qd4cV8P0Iezd8vTi8Xl1Xl9enK50KyoxKJtCs5BCNLovAXBtSIaoOAMaNVo2lTVKoesZaIFUJoWOs8bTYBrBppkbcUO0NvZO07NACsNNnrVy9GbQfmtdMrIvyfWdHLtbiRnoiScJsGbe4F3nyYIUQ4maOh7ZcFNQWaU55RklBUJff0PunGTt-l7iaq4KDPGs0QdzpT2LgQP7eMylMjfocoUqrwLNbGv_tz-kXxIMQHHM3Bretj-3yTfLy9m5S8mebFa</recordid><startdate>201903</startdate><enddate>201903</enddate><creator>Chen, Juan</creator><creator>Schroeder, Jocelyn A.</creator><creator>Luo, Xiaofeng</creator><creator>Montgomery, Robert R.</creator><creator>Shi, Qizhen</creator><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope><scope>K9.</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>201903</creationdate><title>The impact of GPIbα on platelet‐targeted FVIII gene therapy in hemophilia A mice with pre‐existing anti‐FVIII immunity</title><author>Chen, Juan ; Schroeder, Jocelyn A. ; Luo, Xiaofeng ; Montgomery, Robert R. ; Shi, Qizhen</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3589-fb566e990bc4fe96ca0cee563e18bc1b88d4e2f39feeac15c44bc0e6c3ec02f83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Animals</topic><topic>Antibodies - immunology</topic><topic>Bleeding</topic><topic>Blood Platelets - immunology</topic><topic>Blood Platelets - metabolism</topic><topic>Disease Models, Animal</topic><topic>Factor VIII - genetics</topic><topic>Factor VIII - immunology</topic><topic>Factor VIII - metabolism</topic><topic>Factor VIII deficiency</topic><topic>Flow cytometry</topic><topic>FVIII</topic><topic>Gene therapy</topic><topic>Genetic Therapy</topic><topic>GPIbα</topic><topic>Hematopoietic Stem Cell Transplantation</topic><topic>Hematopoietic stem cells</topic><topic>Hematopoietic Stem Cells - metabolism</topic><topic>Hemoglobin</topic><topic>Hemophilia</topic><topic>hemophilia A</topic><topic>Hemophilia A - blood</topic><topic>Hemophilia A - genetics</topic><topic>Hemophilia A - immunology</topic><topic>Hemophilia A - therapy</topic><topic>Hemostasis</topic><topic>Immune response</topic><topic>Immune Tolerance</topic><topic>Immunological memory</topic><topic>Immunological tolerance</topic><topic>Mice, Knockout</topic><topic>Phenotypes</topic><topic>platelet</topic><topic>Platelet Adhesiveness</topic><topic>Platelet Glycoprotein GPIb-IX Complex - genetics</topic><topic>Platelet Glycoprotein GPIb-IX Complex - metabolism</topic><topic>Platelets</topic><topic>Stem cell transplantation</topic><topic>Stem cells</topic><topic>Transduction, Genetic</topic><topic>Von Willebrand factor</topic><topic>von Willebrand Factor - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Chen, Juan</creatorcontrib><creatorcontrib>Schroeder, Jocelyn A.</creatorcontrib><creatorcontrib>Luo, Xiaofeng</creatorcontrib><creatorcontrib>Montgomery, Robert R.</creatorcontrib><creatorcontrib>Shi, Qizhen</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of thrombosis and haemostasis</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chen, Juan</au><au>Schroeder, Jocelyn A.</au><au>Luo, Xiaofeng</au><au>Montgomery, Robert R.</au><au>Shi, Qizhen</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The impact of GPIbα on platelet‐targeted FVIII gene therapy in hemophilia A mice with pre‐existing anti‐FVIII immunity</atitle><jtitle>Journal of thrombosis and haemostasis</jtitle><addtitle>J Thromb Haemost</addtitle><date>2019-03</date><risdate>2019</risdate><volume>17</volume><issue>3</issue><spage>449</spage><epage>459</epage><pages>449-459</pages><issn>1538-7933</issn><issn>1538-7836</issn><eissn>1538-7836</eissn><abstract>Essentials Platelet‐specific FVIII gene therapy is effective in hemophilia A mice even with inhibitors. The impact of platelet adherence via VWF/GPIbα binding on platelet gene therapy was investigated. GPIbα does not significantly affect platelet gene therapy of hemophilia A with inhibitors. Platelet gene therapy induces immune tolerance in hemophilia A mice with pre‐existing immunity. Summary Background We have previously demonstrated that von Willebrand factor (VWF) is essential in platelet‐specific FVIII (2bF8) gene therapy of hemophilia A (HA) with inhibitory antibodies (inhibitors). At the site of injury, platelet adherence is initiated by VWF binding to the platelet GPIb complex. Objective To investigate the impact of GPIbα on platelet gene therapy of HA with inhibitors. Methods Platelet‐FVIII expression was introduced by 2bF8 lentivirus (2bF8LV) transduction of hematopoietic stem cells (HSCs) from GPIbαnull (Ibnull) mice or rhF8‐primed FVIIInull (F8null) mice followed by transplantation into lethally irradiated rhF8‐primed F8null recipients. Animals were analyzed by flow cytometry, FVIII assays and the tail bleeding test. Results After transplantation, 99% of platelets were derived from donors. The macrothrombocytopenia phenotype was maintained in F8null mice that received 2bF8LV‐transduced Ibnull HSCs (2bF8‐Ibnull/F8null). The platelet‐FVIII expression level in 2bF8‐Ibnull/F8null recipients was similar to that obtained from F8null mice that received 2bF8LV‐transduced F8null HSCs (2bF8‐F8null/F8null). The tail bleeding test showed that the remaining hemoglobin level in the 2bF8‐Ibnull/F8null group was significantly higher than in the F8null control group, but there was no significant difference between the 2bF8‐Ibnull/F8null and 2bF8‐F8null/F8null groups. The half‐life of inhibitor disappearance time was comparable between the 2bF8‐Ibnull/F8null and 2bF8‐F8null/F8null groups. The rhF8 re‐challenge did not elicit a memory immune response once inhibitor titers dropped to undetectable levels after 2bF8 gene therapy. Conclusion GPIbα does not significantly impact platelet gene therapy of HA with inhibitors. 2bF8 gene therapy restores hemostasis and promotes immune tolerance in HA mice with pre‐existing immunity.</abstract><cop>England</cop><pub>Elsevier Limited</pub><pmid>30609275</pmid><doi>10.1111/jth.14379</doi><tpages>11</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1538-7933
ispartof Journal of thrombosis and haemostasis, 2019-03, Vol.17 (3), p.449-459
issn 1538-7933
1538-7836
1538-7836
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6397061
source MEDLINE; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection
subjects Animals
Antibodies - immunology
Bleeding
Blood Platelets - immunology
Blood Platelets - metabolism
Disease Models, Animal
Factor VIII - genetics
Factor VIII - immunology
Factor VIII - metabolism
Factor VIII deficiency
Flow cytometry
FVIII
Gene therapy
Genetic Therapy
GPIbα
Hematopoietic Stem Cell Transplantation
Hematopoietic stem cells
Hematopoietic Stem Cells - metabolism
Hemoglobin
Hemophilia
hemophilia A
Hemophilia A - blood
Hemophilia A - genetics
Hemophilia A - immunology
Hemophilia A - therapy
Hemostasis
Immune response
Immune Tolerance
Immunological memory
Immunological tolerance
Mice, Knockout
Phenotypes
platelet
Platelet Adhesiveness
Platelet Glycoprotein GPIb-IX Complex - genetics
Platelet Glycoprotein GPIb-IX Complex - metabolism
Platelets
Stem cell transplantation
Stem cells
Transduction, Genetic
Von Willebrand factor
von Willebrand Factor - metabolism
title The impact of GPIbα on platelet‐targeted FVIII gene therapy in hemophilia A mice with pre‐existing anti‐FVIII immunity
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-12T01%3A27%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20impact%20of%20GPIb%CE%B1%20on%20platelet%E2%80%90targeted%20FVIII%20gene%20therapy%20in%20hemophilia%20A%20mice%20with%20pre%E2%80%90existing%20anti%E2%80%90FVIII%20immunity&rft.jtitle=Journal%20of%20thrombosis%20and%20haemostasis&rft.au=Chen,%20Juan&rft.date=2019-03&rft.volume=17&rft.issue=3&rft.spage=449&rft.epage=459&rft.pages=449-459&rft.issn=1538-7933&rft.eissn=1538-7836&rft_id=info:doi/10.1111/jth.14379&rft_dat=%3Cproquest_pubme%3E2164102135%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2186972362&rft_id=info:pmid/30609275&rfr_iscdi=true